Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

Georgia Fogden-King's Articles

Summit Highlights Microbiome Preservation During Ridinilazole Treatment at ID Week 2017

Summit Highlights Microbiome Preservation During Ridinilazole Treatment  in Exploraroty Phase 2 Clinical Trial at ID Week 2017

Enesi Pharma debuts at World Vaccine Congress

Enesi Pharma, a clinical-stage company developing unique injectable solid dose drug-device combination products, announces its launch as a new company at the World Vaccine Congress

Pertinax Pharma launches patented chlorhexidine technology - Pertinax®

Novel materials enablecontrolled and sustained release of chlorhexidine across a multitude of applications

Piramal Pharma Solutions announces large scale expansion of API manufacturing facilities

Leading Contract Development and Manufacturing Organization (CDMO), announced investments of $55 million across its sites in North America & Asia, to expand its API manufacturing capabilities and capacities. 

Innovate UK is to invest up to £30 million to establish a network of 3 advanced therapies treatment centres in the UK

Evotec Invests in Exscientia to Advance AI-Driven Drug Discovery

Evotec has made a € 15 M investment to take a minority stake in Exscientia.

Arecor Announces License Agreement With Global Pharmaceutical Company

Global pharmaceutical and healthcare company, has exercised its license option to Arecor’s proprietary formulation technology, to develop differentiated biosimilar products.

DNAe Previews its Semiconductor Genomic Analysis Test to Address the Challenge of Sepsis

LiDia™ Bloodstream Infection (BSI) Test showcased at an Imperial College/Royal Institution Technology vs Infectious Diseases Summit, London

Cell-line Derived Controls for Diagnostic Assay Development

AMSBIO announce the addition of mutation cell line Formalin-Fixed Paraffin-Embedded (FFPE) samples and isolated genomic DNA (gDNA) controls to its extensive range of cell line reference standards.

Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial

This is the Company’s second orally-active small molecule cancer therapeutic agent to enter clinical trials during the past 12 months.

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us,, and we will post.